Epizyme Inc (EPZM)

17.05
0.20 1.20
NASDAQ : Health Care
Prev Close 17.25
Open 17.20
Day Low/High 16.95 / 17.30
52 Wk Low/High 8.27 / 23.35
Volume 153.30K
Avg Volume 431.90K
Exchange NASDAQ
Shares Outstanding 58.25M
Market Cap 1.01B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Epizyme President Of Research And Chief Scientific Officer, Robert Copeland, Announces Retirement From The Company

Epizyme President Of Research And Chief Scientific Officer, Robert Copeland, Announces Retirement From The Company

Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition

First Week of EPZM April 21st Options Trading

First Week of EPZM April 21st Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the April 21st expiration.

Epizyme is Now Oversold (EPZM)

Epizyme is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting EPZM Put And Call Options For August 18th

Interesting EPZM Put And Call Options For August 18th

Investors in Epizyme Inc. saw new options begin trading this week, for the August 18th expiration.

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Investors considering a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Robert A. Copeland, Ph.D., recognized for his insights into epigenetic targets contributing to the development of novel investigational medicines

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Studies Will Evaluate Tazemetostat and Pinometostat in Multiple Cancer Indications

Epizyme Establishes Collaboration With Foundation Medicine To Support Tazemetostat Phase 2 Clinical Trial

Epizyme Establishes Collaboration With Foundation Medicine To Support Tazemetostat Phase 2 Clinical Trial

Foundation Medicine Will Identify Individuals with Non-Hodgkin Lymphoma whose Tumors Possess EZH2 Mutations for Potential Enrollment into Epizyme's Phase 2 Clinical Trial

First Week of EPZM May 2017 Options Trading

First Week of EPZM May 2017 Options Trading

Investors in Epizyme Inc. saw new options become available this week, for the May 2017 expiration.

Epizyme Earns $6 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development With First-in-Class PRMT5 Inhibitor

Epizyme Earns $6 Million Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development With First-in-Class PRMT5 Inhibitor

Third Epizyme-discovered product candidate advances into clinical development

Epizyme Doses First Patient In Global Phase 2 Study Evaluating Tazemetostat In Mesothelioma

Epizyme Doses First Patient In Global Phase 2 Study Evaluating Tazemetostat In Mesothelioma

Study Expands Tazemetostat Clinical Program into Patients with Relapsed or Refractory Mesothelioma Characterized by BAP1 Loss-of-Function

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Epizyme Initiates Collaboration On Combination Trial Of Tazemetostat And Tecentriq™ (atezolizumab) For Treatment Of Non-Hodgkin Lymphoma

Epizyme Initiates Collaboration On Combination Trial Of Tazemetostat And Tecentriq™ (atezolizumab) For Treatment Of Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of...

First Week of EPZM February 2017 Options Trading

First Week of EPZM February 2017 Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2017 expiration.

Trade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate

Epizyme Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At ASH Lymphoma Biology Meeting

Epizyme Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At ASH Lymphoma Biology Meeting

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported preliminary data from its ongoing, global Phase 2 clinical trial of orally administered...

Epizyme (EPZM): Today's Weak On High Volume Stock

Epizyme (EPZM): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate